Tagraxofusp

CD123 Antibody Toxin Congregate (CD123 ATC; Tagraxofusp) Combined With Azacitidine for Maintenance Therapy Post Allogeneic Hematopoietic Cell Transplantation for Patients With CD123-Positive Malignant

More Information

Trial Status
Accepting patients
Trial Phase
Phase 1
Enrollment
43 patients (estimated)
Sponsors
City of Hope Medical Center
Collaborators
National Cancer Institute (NCI)
Tags
CD123, Post-Allogeneic Stem Cell Transplant
Trial Type
Treatment
Last Update
2 weeks ago
SparkCures ID
2015
NCT Identifier
NCT06498973

Real People. Real Support.

Need help connecting with this clinical trial? We're here to help!

Print a patient-friendly report to share with your patient.

We can help answer any questions and connect you (or your patient) with the study team.

Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.